Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Potential Risk of Hepatitis B Reactivation After Treatment With BCR-ABL Tyrosine Kinase Inhibitors

Need for HBV testing before treatment with TKIs targeting the BCR-ABL
07 Sep 2016
Cytotoxic Therapy

Swissmedic, Swiss agency for the authorisation and supervision of therapeutic products (medicinal products and medical devices), announced on 17 August 2016 that the marketing authorisation holders of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL bosutinib (Bosulif®), dasatinib (Sprycel®), imatinib (Gleevec®, Glivec® GIST, Imatinib Sandoz, Imatinib Teva®, Imatinib Zentiva®), nilotinib (Tasigna®), and ponatinib (Iclusig®) communicated about potential risk of hepatitis B virus (HBV) reactivation after treatment with these drugs.  

In patients who are chronic HBV carriers, cases of HBV reactivation have occurred after receiving the TKIs targeting the BCR-ABL. Some cases of HBV reactivation induced acute liver failure or fulminant hepatitis, which led to a liver transplant or death.


Patients should be tested for the presence of HBV infection before initiating treatment with TKI targeting the BCR-ABL.

Experts in the field of liver disease and with experience in the treatment of HBV infection should be consulted prior to initiating therapy with TKIs targeting the BCR-ABL in patients with positive serology for HBV, including those patients with active disease, and in patients with a positive test for HBV infection during the treatment.

The HBV carriers who require treatment with TKIs targeting the BCR-ABL TKIs should be closely monitored for any signs or symptoms of active HBV infection throughout the treatment and several months after discontinuation of treatment.

The marketing authorisation holders of these BCR ABL TKIs are Ariad Pharmaceuticals (Europe) Sàrl, Bristol-Myers Squibb SA, Novartis Pharma Switzerland AG, Pfizer AG, Helvepharm AG, Sandoz Pharmaceuticals AG and Teva Pharma AG. 

Last update: 07 Sep 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.